Pharmacists, parallel trade and the pandemic
This article was originally published in Scrip
Executive Summary
Parallel trade is guaranteed to cause controversy at the best of times. Pharmaceutical companies say that it deprives them of revenues in the importing country and benefits nobody but the parallel traders themselves. The traders counter that their business is perfectly legal within the EU and insist it helps bring down drug expenditures for both payers and patients.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.